Stock Scorecard
Stock Summary for Exicure Inc (XCUR) - $0.60 as of 4/18/2024 3:23:15 PM EST
Total Score
18 out of 29
Currently on the following lists
None
Tim's Recommendation
Possible Buy
Growth List Algorithm Criteria for XCUR
Positive earnings growth | |
P/E ratio less than Industry P/E Ratio | |
P/E ratio less than Sector P/E Ratio | |
P/E ratio that is half the growth rate (or less) | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Positive net income past year and 12 trailing months | |
Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for XCUR
Revenue growing by at least 20% average per year over the last 5 years | |
Market Capitalization under 2 billion | |
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for XCUR
Declared an ex-dividend date | |
Forward annual dividend rate greater than 2 | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Current ratio most recent quarter greater than 2 |
Bonus Criteria for XCUR
P/E ratio less than five-year Average P/E ratio | |
Last Price to 52 Week Low Ratio Less Than 1 | |
Total Cash Per Share > Last Day Price | |
P/S Ratio < 1 | |
P/B Ratio < 1 |
Latest News for for XCUR
Financial Details for XCUR
Company Overview |
|
---|---|
Ticker | XCUR |
Company Name | Exicure Inc |
Country | USA |
Description | Exicure, Inc., a clinical-stage biotechnology company, develops therapies for neurology, immuno-oncology, inflammatory diseases, and genetic disorders based on its proprietary spherical nucleic acid (SNA) technology. The company is headquartered in Chicago, Illinois. |
Sector Name | LIFE SCIENCES |
Industry Name | PHARMACEUTICAL PREPARATIONS |
Most Recent Quarter | 6/30/2023 |
Next Earnings Date | N/A |
Stock Price History |
|
Last Day Price | 0.60 |
Last Day Price Updated | 4/18/2024 3:23:15 PM EST |
Last Day Volume | 31,098 |
Average Daily Volume | 40,172 |
52-Week High | 1.50 |
52-Week Low | 0.36 |
Last Price to 52 Week Low | 66.67% |
Valuation Measures |
|
Trailing PE | 0.34 |
Industry PE | 100.90 |
Sector PE | 61.34 |
5-Year Average PE | -1.81 |
Free Cash Flow Ratio | 2.22 |
Industry Free Cash Flow Ratio | 12.64 |
Sector Free Cash Flow Ratio | 30.17 |
Current Ratio Most Recent Quarter | 2.56 |
Total Cash Per Share | 0.27 |
Book Value Per Share Most Recent Quarter | 1.12 |
Price to Book Ratio | 0.52 |
Industry Price to Book Ratio | 5.66 |
Sector Price to Book Ratio | 22.08 |
Price to Sales Ratio Twelve Trailing Months | 0.21 |
Industry Price to Sales Ratio Twelve Trailing Months | 5.48 |
Sector Price to Sales Ratio Twelve Trailing Months | 5.19 |
Share Statistics |
|
Total Shares Outstanding | 8,648,300 |
Market Capitalization | 5,188,980 |
Institutional Ownership | N/A |
Dividends |
|
Ex-Dividend Date | N/A |
Last Dividend Amount | 0.00 |
Current Dividend Amount | 0.00 |
Dividend Aristocrat? | False |
Trailing Annual Dividend Rate | 0.00 |
Trailing Annual Dividend Yield | 0.00% |
Forward Annual Dividend Rate | 0.00 |
Forward Annual Dividend Yield | 0.00% |
5-Year Dividend Payments Count | 0 |
3-Year Average Dividend Yield | 0.00% |
5-Year Average Dividend Yield | 0.00% |
1-Year Dividend Growth Rate Percentage | 0.00% |
3-Year Dividend Growth Rate Percentage | 0.00% |
5-Year Dividend Growth Rate Percentage | 0.00% |
All-Time Dividend Growth Rate Percentage | 0.00% |
Dividend Payout Ratio | N/A |
Income Statement |
|
Quarterly Earnings Growth YOY | 0.00% |
Annual Earnings Growth | 95.97% |
Reported EPS 12 Trailing Months | 1.77 |
Reported EPS Past Year | 0.00 |
Reported EPS Prior Year | -0.70 |
Net Income Twelve Trailing Months | 3,065,000 |
Net Income Past Year | -2,582,000 |
Net Income Prior Year | -64,102,000 |
Quarterly Revenue Growth YOY | 928.00% |
5-Year Revenue Growth | 24.29% |
Balance Sheet |
|
Total Cash Most Recent Quarter | 2,335,000 |
Total Cash Past Year | 8,577,000 |
Total Cash Prior Year | 39,141,000 |
Net Cash Position Most Recent Quarter | 2,335,000 |
Net Cash Position Past Year | 8,577,000 |
Long Term Debt Past Year | 0 |
Long Term Debt Prior Year | 6,873,000 |
Total Debt Most Recent Quarter | 0 |
Equity to Debt Ratio Past Year | 1.00 |
Equity to Debt Ratio Most Recent Quarter | 1.00 |
Total Stockholder Equity Past Year | 14,922,000 |
Total Stockholder Equity Prior Year | 11,232,000 |
Total Stockholder Equity Most Recent Quarter | 9,705,000 |
Options |
|
Put/Call Ratio | 0.00 |
Has Options | False |
Liquidity Rating | None |
Technical Analysis |
|
Yahoo Finance Chart | Yahoo Finance Chart |
MACD | -0.01 |
MACD Signal | -0.01 |
20-Day Bollinger Lower Band | 0.47 |
20-Day Bollinger Middle Band | 0.61 |
20-Day Bollinger Upper Band | 0.75 |
Beta | 1.23 |
RSI | 51.68 |
50-Day SMA | 0.77 |
200-Day SMA | 21.91 |
System |
|
Modified | 4/18/2024 3:24:01 PM EST |